3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
41
Lung Neoplasms
15
Neoplasms
2
NSCLC
2
Breast Neoplasms
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Sexual Dysfunction, Physiological
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Small Cell Lung Cancer With EGFR Mutation
1
Non Small Cell Lung Cancer Metastatic
1
NSCLC Patients With Brain Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Mesothelioma
1
Meningeal Carcinomatosis
1
Lung Cancer Metastatic
1
Locally Advanced or Metastatic Non-squamous NSCLC
1
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
1
Lethal Congenital Contracture Syndrome 2
1
Head and Neck Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Advanced Solid Tumors
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
1
osimertinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Paroxetine
1
Paclitaxel
1
Itraconazole
1
Docetaxel
1
Carboplatin
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lethal Congenital Contracture Syndrome 2
×
osimertinib
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled